Among the patients receiving intensive consolidation therapy, the OS tended to be better in patients with CBFβ-MYH11+ AML than in those with RUNX1-RUNXIT1+ AML(P=0.062). The gene discussed is RUNX1; the disease is acute myeloid leukemia.